Table 1.

Dose of drug that inhibited 50 % growth of human thyroid cancer cell line in vitro

Cell line	Mutation/arrangements	IC50 (nM) Belinostat	IC50 (nM) Panobinostat	IC50 (nM) Dasatinib	IC50 (μM) Sorafenib	IC50 (nM) Pazopanib	IC50 Motesanib
Cal62	KRAS	470 ± 36	33 ± 4	35 ± 5	13 ± 1.1	NR	NR
Hth7	NRAS	400 ± 56	15 ± 2	NR	6.8 ± 0.8	NR	NR
Hth83	HRAS	720 ± 100	34 ± 5	NR	11 ± 1.0	NR	NR
C643	HRAS	970 ± 120	71 ± 10	NR	6.5 ± 0.9	NR	NR
SW1736	BRAF	380 ± 40	35 ± 8	NR	NR	NR	NR
T241	Nil	750 ± 65	65 ± 7	NR	7.5 ± 0.5	NR	NR
T351	Nil	1,100 ± 170	50 ± 10	NR	11 ± 2.0	NR	NR
BHP2-7	RET/PTC	770 ± 67	37 ± 6	47 ± 3	5.0 ± 0.8	340 ± 20	NR
T238	PI3 K/BRAF	6,800 ± 740	1,500 ± 200	NR	6.5 ± 1.2	NR	NR

Tabulated results of HDACI (belinostat and panobinostat) and tyrosine kinase inhibitor (TKI dasatinib, sorafenib, pazopanib and motesanib)-treated thyroid cancer cell lines at 72 h of drug exposure. Mean 50 % inhibitory concentration (IC50 ± SD) of experiments done in triplicate experiments with each experiment done with triplicate wells using MTT assay. Nil: No mutations detected. NR: IC50 not reached (i.e., pharmacologically relevant IC50 not reached). See “Materials and methods” for details